Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2Withdrawn 1Unknown 1Suspended 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Abdominal Neoplasms 1

Interventions

pembrolizumab 85Cyclophosphamide 74Nivolumab 58fludarabine 49Specimen Handling 49Magnetic Resonance Spectroscopy 43Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 30atezolizumab 27Gemcitabine 27Paclitaxel 26Ipilimumab 26Cisplatin 24venetoclax 23Radiation 23Dexamethasone 22Radiosurgery 21durvalumab 20Rituximab 20Temozolomide 18Lenalidomide 18Bevacizumab 17palbociclib 15Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Cell Count × Clear all
NCT05617755 2025-07-30

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Arsenal Biosciences, Inc.

Phase 1 Active not recruiting
19 enrolled
Gynecologic

Abdominal Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡